PATENT CLAIM ANALYSIS

Application Number: 16174005
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["424", "134100"]

Abstract:
Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

Claim (Index 16):
The genetically engineered human hematopoietic cell of  claim 15 , wherein the CRISPR system cleaves the endogenous gene encoding the lineage-specific cell-surface antigen in one or more exon(s) of the gene.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.26923
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16174089', '15655432', '14303331', '15970605', '14358828']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7704272963062346
- 35 USC 102 Novelty (BERT): 0.6251682347182618
- Combined Prediction Score: 0.7559013901474374
- Mean Citation Score: 539.340736
- Max Citation Score: 764.79987
- Similarity Product: 503.0161698764832

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test